EU Antitrust Watchdog Probes Aspen's Cancer Med Pricing
The European Union's competition authority has opened an investigation into whether South Africa-based Aspen Pharmacare Holdings Ltd. has violated antitrust law by imposing unjustified price increases on five cancer medications, the...To view the full article, register now.
Already a subscriber? Click here to view full article